Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

Coating compositions, coated articles including the coating compositions, and methods of making the coating compositions and coated articles are provided. In some aspects, the coating compositions are applied to a substrate having nitric oxide-releasing properties. The coating compositions can include copolymers having crosslinking agents that can be activated with mild UV light (about 345 nm to 365 nm) to avoid damaging the substrate while creating strong covalent bonds to the substrate. The copolymers can include hydrophilic repeat units, and in particular zwitterionic repeat units such as repeat units containing phosphorylcholine groups. In some aspects, the coating compositions are applied to a surface of a polymer substrate, wherein the polymer substrate had nitric oxide releasing properties. The coating compositions and the coated articles can have antifouling, antithrombotic, and/or antibacterial properties.

An artificial ligament prosthesis which is notable in that it comprises a layer totally or partly consisting of PCL fibres. The ligament prosthesis is a biodegradable and “biointegrable” artificial ligament which makes it possible to take away all the apprehensions and uncertainties due to non-degradable synthetic supports. It is a prosthetic structure inspired by and similar to the native tissue, which is biodegradable while being sterilisable. It can optionally be seeded in order to facilitate the formation of functional tissues with controlled cell and tissue activity, having the required mechanical properties. The prosthesis maybe slowly resorbable in order to be gradually replaced with a functional tissue identical to that of the native ligament.

A dressing that includes an absorbent, antimicrobial layer and a bioresorbable layer is disclosed herein. The absorbent, antimicrobial layer may be formed from nonwoven fibers. The bioresorbable layer may include an extracellular polymeric substance-active agent, such as citric acid. At least a portion of the nonwoven fibers may include carboxymethylcellulose fibers and alginate fibers.

This disclosure relates to sclerostin inhibitors for use in ossification, and methods related thereto. In certain embodiments, the disclosure relates to placing sclerostin inhibitors in graft compositions for forming bone. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a graft composition disclosed herein optionally comprising a growth factor such as BMP or recombinant vector expressing the same in a subject such as at a desired site of bone or cartilage growth.

Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

The present invention relates to compositions based on: (a) a glycosaminoglycan or mixtures thereof; (b) one or more tocopherols, tocotrienols and mixtures thereof; and (c) a selected stabilizer. The composition is a solution, with the agents not chemically bound with each other. The component (a) can be hyaluronic acid (HA) or a salt thereof; the component (b) can be a polyether clathrate a cyclodextrin, or a combination of a fatty acid with an emulsifier; the component (c) can be α-tocopherols, β-tocopherols, γ-tocopherols, δ-tocopherols; α-tocotrienols, β-tocotrienols, γ-tocotrienols, δ-tocotrienols. Preferably component (c) is vitamin E. The agents strongly cooperate to provide enhanced and more stable viscoelastic properties, resulting in a product with higher resistance to thermal treatments like e.g. heat-sterilization, autoclaving, etc. The present compositions, optionally loaded with pharmaceutically and/or cosmetically active agents, are advantageously used in medical or cosmetic methods.

An embodiment includes a system comprising a thermoset polyurethane shape memory polymer (SMP) foam that includes at least one antimicrobial agent. The antimicrobial agent may include at least one phenolic acid that is a pendent group chemically bonded to a polyurethane polymer chain of the SMP foam. Other embodiments are described herein.

A Delivery System for delivery of an Active Component is provided. The Delivery System comprises a Delivery Matrix and an Active Component. The Delivery Matrix has one or both of (i) a Cationic Component; and (ii) a Matrix Forming Substance. The Cationic Component has one or both of: (i) a cationic polymer or cationic copolymer, and (ii) a positively charged non-polymeric compound or composition. The Active Component comprises a cationic bioactive. The Delivery Matrix has a mEq amount of positive charge which is equal to or exceeds the mEq amount of positive charge of the Active Component. The Delivery Matrix may comprise chitosan, or other biopolymers, synthetic polymers, matrix polymers and large molecules, which themselves are matrix forming, or are combined with a Matrix Forming Substance and one or more other Cationic Components to form the positively charged Delivery Matrix.